Weekly intensive versus standard chemotherapy in untreated small cell lung cancer (SCLC) patients with good prognosis

ISRCTN	ISRCTN26181691
DOI	https://doi.org/10.1186/ISRCTN26181691
Secondary identifying numbers	TR6SCLC

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study design	Randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Scientific title	Weekly intensive versus standard chemotherapy in untreated small cell lung cancer (SCLC) patients with good prognosis
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Lung (small cell) cancer
Intervention	1. Intensive Regimen: Chemotherapy, cisplatin and etoposide alternating every 7 days with ifosfamide and adriamycin. A total of twelve courses, six with each drug combination. 2. Standard Regimen: Chemotherapy, cisplatin and etoposide alternating every 21 days with ifosfamide and adriamycin. A total of six courses, three with each drug combination. All limited disease patients who show complete or partial response following chemotherapy receive thoracic irradiation.
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Not Applicable
Drug / device / biological / vaccine name(s)	Cisplatin, etoposide, ifosfamide, adriamycin
Primary outcome measure	Not provided at time of registration
Secondary outcome measures	Not provided at time of registration
Overall study start date	01/01/1988
Completion date	31/12/1992

Participant type(s)	Patient
Age group	Adult
Sex	Both
Target number of participants	Not provided at time of registration
Key inclusion criteria	1. Histologically or cytologically proven SCLC 2. Age 75 or under 3. Either limited disease or extensive disease in the good prognostic category. That is have both of the following characteristics, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and alkaline phosphatase <1.5 upper limit of normal range 4. Adequate renal function 5. No previous malignancy, except non-melanomatous skin cancer 6. No previous chemotherapy or radiotherapy 7. No medical contraindications to treatment
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/1988
Date of final enrolment	31/12/1992

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Charity

Cancer Research UK
Private sector organisation / Other non-profit organizations

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

15/01/2019: No publications found. All search options exhausted.